Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.43 |
| ▸ | PTGES | O14684 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7189255 | 0.98 | PLA2G4B (0.43) | PPARGPPARAALOX5PTGESTHRB | |
| Lithium SCHEMBL7188712 | 0.98 | PPARG (0.43) | PPARGPPARAALOX5PTGESPPARD | |
| SCHEMBL7189260 | 0.96 | PLA2G4B (0.45) | THRBPLA2G4BPTPN11TP53TSHR | |
| SCHEMBL7179721 | 0.95 | KMT2A (0.43) | PPARGPPARAALOX5PTGESPPARD | |
| Lithium SCHEMBL7179726 | 0.93 | KMT2A (0.43) | PPARGPPARAALOX5PTGESPPARD | |
| SCHEMBL7177654 | 0.92 | PPARG (0.39) | PPARGPPARAALOX5PTGESPPARD | |
| SCHEMBL7181077 | 0.90 | ITGB1 (0.45) | PPARGPPARAALOX5PTGESPPARD | |
| SCHEMBL7177730 | 0.90 | PLA2G4B (0.39) | PPARGPPARAALOX5PTGESPPARD | |
| SCHEMBL7188475 | 0.90 | THRB (0.41) | PPARGPPARAALOX5PTGESPPARD | |
| Lithium SCHEMBL7177659 | 0.90 | PPARG (0.39) | PPARGPPARAALOX5PTGESPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | PPARG 2956/4885PPARA 3039/4885ALOX5 1863/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | PPARG 2776/4885PPARA 2624/4885ALOX5 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.